Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

GE Healthcare to evaluate and develop molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin.

Under the license GE Healthcare will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

The probes bind to dead and dying cells making them useful for detecting acute cell injury and cell death. When the active component of this molecule is attached to a radioactive tracer, it can be used in nuclear medicine imaging techniques, such as PET ( positron emission tomography ) or SPECT ( single photon emission computed tomography ), to produce three-dimensional images of where this cell death is occurring.

"We are pleased to be working with GE Healthcare on this technology," said Dennis Devitt, the director of marketing and licensing for the Office of Technology Development (OTD), the technology transfer arm of the Medical College. "Working with the market leader in medical imaging allows this technology to be quickly moved from the research laboratory into patient care," Devitt said.

Source: GE Healthcare

You can discuss about GE Healthcare and its products & services in the GE Healthcare User Group